Fennec Pharmaceuticals Inc. (FENC) EPS Estimated At $-0.15

March 15, 2018 - By Winifred Garcia

 Fennec Pharmaceuticals Inc. (FENC) EPS Estimated At $ 0.15

Analysts expect Fennec Pharmaceuticals Inc. (NASDAQ:FENC) to report $-0.15 EPS on March, 29.They anticipate $0.07 EPS change or 87.50 % from last quarter’s $-0.08 EPS. After having $-0.15 EPS previously, Fennec Pharmaceuticals Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.59% or $0.06 during the last trading session, reaching $9.43. About 68,977 shares traded or 190.92% up from the average. Fennec Pharmaceuticals Inc. (NASDAQ:FENC) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The company has market cap of $173.62 million. The Company’s lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. It currently has negative earnings. The firm was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

More notable recent Fennec Pharmaceuticals Inc. (NASDAQ:FENC) news were published by: Streetinsider.com which released: “Wedbush Starts Fennec Pharmaceuticals (FENC) at Outperform” on March 12, 2018, also Globenewswire.com with their article: “Fennec Pharmaceuticals Announces Listing on the Nasdaq Capital Market” published on September 11, 2017, Globenewswire.com published: “Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK …” on October 16, 2017. More interesting news about Fennec Pharmaceuticals Inc. (NASDAQ:FENC) were released by: Marketwatch.com and their article: “Fennec Pharmaceuticals Inc.” published on October 15, 2017 as well as Globenewswire.com‘s news article titled: “Fennec Announces Pricing of Public Offering” with publication date: December 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: